Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Faisal Hayat

Interventional Cardiology Dayton, OH Medical Doctor

NPI 1336354653 CMS profile 105613

4160 Little York Rd Ste 20, Dayton, OH 45414

Open in the dashboard

General payments

$2,892

73 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Faisal Hayat of Dayton, OH is reported in the CMS Open Payments database as having received $2,892 across 73 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 26th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $66 1
2022 General $487 4
2021 General $421 13
2019 General $1,919 55

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Faisal Hayat
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Faisal Hayat were reported at $0. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Faisal Hayat Interventional Cardiology median Middle half National median
2019 $1,919 $1,097 $329–$3,048 $163
2020 $0 $473 $161–$1,480 $114
2021 $421 $677 $233–$1,827 $132
2022 $487 $978 $333–$2,724 $149
2023 $66 $1,136 $382–$2,986 $160
2024 $0 $1,181 $395–$3,326 $164
2025 $0 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Edwards Lifesciences Corporation $1,362 12 payments
  2. Shockwave Medical, Inc $531 3 payments
  3. Abbott Laboratories $346 12 payments
  4. Novartis Pharmaceuticals Corporation $277 22 payments
  5. Abiomed $81 2 payments
  6. Amgen Inc. $49 4 payments
  7. AstraZeneca Pharmaceuticals LP $38 3 payments
  8. Cardiovascular Systems Inc. $28 1 payment
  9. E.R. Squibb & Sons, L.L.C. $25 2 payments
  10. Bardy Diagnostics, Inc. $25 1 payment
  11. Other $129 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $1,751 70 payments
  2. Travel and Lodging $1,142 3 payments
Products named General payments · program years 2019–2023
  1. Edwards SAPIEN 3 Transcatheter Heart Valve $1,362 12 payments
  2. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $316 2 payments
  3. ENTRESTO $262 21 payments
  4. Vascular Lithotripsy $215 1 payment
  5. CARDIOMEMS $156 1 payment
  6. PressureWire FFR $100 1 payment
  7. Impella $81 2 payments
  8. CardioMEMS HF System $79 9 payments
  9. Repatha $49 4 payments
  10. Corlanor $49 4 payments
  11. Other $277 20 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 47 drugs

Part D claims

5,069

Median for Interventional Cardiology: 2,236

Drug cost

$653,310

Median for Interventional Cardiology: $380,412

Branded share of claims

22.5%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 435 $431,844
Entresto Sacubitril/Valsartan Brand 66 $77,894
Xarelto Rivaroxaban Brand 30 $30,748
Brilinta Ticagrelor Brand 25 $23,372
Farxiga Dapagliflozin Propanediol Brand 25 $20,935
Corlanor Ivabradine Hcl Brand 13 $15,445
Ranolazine Er Ranolazine Brand 65 $8,076
Amiodarone Hcl Generic 69 $6,037
Metoprolol Succinate Generic 591 $5,668
Midodrine Hcl Generic 15 $3,263

The 10 drugs with the highest cost, of 47 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 68 billing codes

Paid by Medicare

$88,202

Medicare's payments for the services billed

Medicare patients

523

Average age 74

Services billed

1,526

268 women, 255 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 53%
Arthritis 52%
Diabetes 41%
Heart failure 38%
Chronic kidney disease 36%
Atrial fibrillation 32%
COPD 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

73 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record